vs
ANI PHARMACEUTICALS INC（ANIP）とNational Storage Affiliates Trust（NSA）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $187.0M、National Storage Affiliates Trustの約1.3倍）。National Storage Affiliates Trustの純利益率が高く（12.2% vs 11.1%、差は1.1%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -1.6%）。National Storage Affiliates Trustの直近四半期フリーキャッシュフローが多い（$299.8M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -2.4%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ナショナル・ストレージ・アフィリエイツ・トラストは米国に本拠を置く不動産投資信託で、セルフストレージ事業を中心に、米国数十州の施設の所有・運営・買収を行い、個人や企業向けに安全な保管サービスを提供しています。
ANIP vs NSA — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $187.0M |
| 純利益 | $27.5M | $22.9M |
| 粗利率 | — | 72.5% |
| 営業利益率 | 14.1% | 20.2% |
| 純利益率 | 11.1% | 12.2% |
| 売上前年比 | 29.6% | -1.6% |
| 純利益前年比 | 367.5% | 36.8% |
| EPS（希薄化後） | $1.14 | $0.23 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $187.0M | ||
| Q3 25 | $227.8M | $188.7M | ||
| Q2 25 | $211.4M | $188.8M | ||
| Q1 25 | $197.1M | $188.4M | ||
| Q4 24 | $190.6M | $190.1M | ||
| Q3 24 | $148.3M | $193.6M | ||
| Q2 24 | $138.0M | $190.4M | ||
| Q1 24 | $137.4M | $196.1M |
| Q4 25 | $27.5M | $22.9M | ||
| Q3 25 | $26.6M | $18.4M | ||
| Q2 25 | $8.5M | $19.5M | ||
| Q1 25 | $15.7M | $13.0M | ||
| Q4 24 | $-10.3M | $16.7M | ||
| Q3 24 | $-24.2M | $18.7M | ||
| Q2 24 | $-2.3M | $17.1M | ||
| Q1 24 | $18.2M | $59.0M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 70.7% | ||
| Q2 25 | — | 70.5% | ||
| Q1 25 | — | 70.7% | ||
| Q4 24 | — | 72.5% | ||
| Q3 24 | — | 72.8% | ||
| Q2 24 | — | 72.6% | ||
| Q1 24 | — | 72.1% |
| Q4 25 | 14.1% | 20.2% | ||
| Q3 25 | 15.9% | 15.8% | ||
| Q2 25 | 6.6% | 16.5% | ||
| Q1 25 | 13.3% | 11.0% | ||
| Q4 24 | -2.3% | 14.5% | ||
| Q3 24 | -13.8% | 15.8% | ||
| Q2 24 | 3.7% | 17.2% | ||
| Q1 24 | 14.8% | 48.9% |
| Q4 25 | 11.1% | 12.2% | ||
| Q3 25 | 11.7% | 9.8% | ||
| Q2 25 | 4.0% | 10.3% | ||
| Q1 25 | 8.0% | 6.9% | ||
| Q4 24 | -5.4% | 8.8% | ||
| Q3 24 | -16.3% | 9.7% | ||
| Q2 24 | -1.7% | 9.0% | ||
| Q1 24 | 13.2% | 30.1% |
| Q4 25 | $1.14 | $0.23 | ||
| Q3 25 | $1.13 | $0.17 | ||
| Q2 25 | $0.36 | $0.19 | ||
| Q1 25 | $0.69 | $0.10 | ||
| Q4 24 | $-0.45 | $0.19 | ||
| Q3 24 | $-1.27 | $0.18 | ||
| Q2 24 | $-0.14 | $0.16 | ||
| Q1 24 | $0.82 | $0.65 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $23.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $946.0M |
| 総資産 | $1.4B | $5.1B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $23.3M | ||
| Q3 25 | $262.6M | $26.3M | ||
| Q2 25 | $217.8M | $26.1M | ||
| Q1 25 | $149.8M | $19.3M | ||
| Q4 24 | $144.9M | $50.4M | ||
| Q3 24 | $145.0M | $69.9M | ||
| Q2 24 | $240.1M | $59.0M | ||
| Q1 24 | $228.6M | $64.2M |
| Q4 25 | $540.7M | $946.0M | ||
| Q3 25 | $505.8M | $973.1M | ||
| Q2 25 | $436.8M | $1.0B | ||
| Q1 25 | $418.6M | $1.0B | ||
| Q4 24 | $403.7M | $1.1B | ||
| Q3 24 | $405.9M | $986.9M | ||
| Q2 24 | $455.8M | $1.2B | ||
| Q1 24 | $452.0M | $1.3B |
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.3B | $5.2B | ||
| Q1 25 | $1.3B | $5.3B | ||
| Q4 24 | $1.3B | $5.4B | ||
| Q3 24 | $1.3B | $5.4B | ||
| Q2 24 | $920.8M | $5.3B | ||
| Q1 24 | $914.5M | $5.4B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $338.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $299.8M |
| FCFマージンFCF / 売上 | 11.8% | 160.3% |
| 設備投資強度設備投資 / 売上 | 0.5% | 20.7% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 14.79× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $541.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $338.5M | ||
| Q3 25 | $44.1M | $100.2M | ||
| Q2 25 | $75.8M | $79.9M | ||
| Q1 25 | $35.0M | $85.6M | ||
| Q4 24 | $15.9M | $363.1M | ||
| Q3 24 | $12.5M | $105.7M | ||
| Q2 24 | $17.4M | $83.2M | ||
| Q1 24 | $18.3M | $94.0M |
| Q4 25 | $29.1M | $299.8M | ||
| Q3 25 | $38.0M | $88.0M | ||
| Q2 25 | $71.8M | $73.8M | ||
| Q1 25 | $32.5M | $79.9M | ||
| Q4 24 | $13.5M | $344.4M | ||
| Q3 24 | $7.7M | $101.8M | ||
| Q2 24 | $13.0M | $79.5M | ||
| Q1 24 | $13.7M | $88.6M |
| Q4 25 | 11.8% | 160.3% | ||
| Q3 25 | 16.7% | 46.6% | ||
| Q2 25 | 34.0% | 39.1% | ||
| Q1 25 | 16.5% | 42.4% | ||
| Q4 24 | 7.1% | 181.2% | ||
| Q3 24 | 5.2% | 52.6% | ||
| Q2 24 | 9.4% | 41.7% | ||
| Q1 24 | 10.0% | 45.2% |
| Q4 25 | 0.5% | 20.7% | ||
| Q3 25 | 2.7% | 6.5% | ||
| Q2 25 | 1.9% | 3.2% | ||
| Q1 25 | 1.3% | 3.0% | ||
| Q4 24 | 1.3% | 9.8% | ||
| Q3 24 | 3.2% | 2.0% | ||
| Q2 24 | 3.2% | 1.9% | ||
| Q1 24 | 3.3% | 2.7% |
| Q4 25 | 1.10× | 14.79× | ||
| Q3 25 | 1.66× | 5.44× | ||
| Q2 25 | 8.87× | 4.10× | ||
| Q1 25 | 2.23× | 6.59× | ||
| Q4 24 | — | 21.70× | ||
| Q3 24 | — | 5.65× | ||
| Q2 24 | — | 4.88× | ||
| Q1 24 | 1.00× | 1.59× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
NSA
セグメントデータなし
